T H E C A R D IO V A S C U LA R D IS EA S E, M Y O CA RD ITIS
, is characterized by inflam mation and necrosis of cardiac muscle. The disease is associated with heart failure, arrhythm ia, and sudden death. Myocarditis patients may have myocardial infarctions associated with severe chest pain, electrocardiograp hic changes, and elevated serum levels of creatine kinase. (1) The disease may be induced by a number of physical, chemical, and infectious agents, including viruses. (2) Viral myocarditis has been linked with the subsequent development of dilated cardiomyopathy , a disease that accounts for approximately 25% of all heart failures in North America. (3, 4) Viruses associated with myocarditis include, picornaviruses, orthom yxoviruses, and the herpesviruses. Human cytom egalovirus (CMV), a herpesvirus that is ubiquitous in human populations, is associated with seropositivity, often exceeding 50% in adults of developed countries. Overt disease is rare in immunocompete nt individuals, but may follow blood transfusions resulting in a number of clinical manifestations, including myocarditis. (5) Active CMV infection is a common major complication in heart transplant recipients and patients with AIDS, resulting in allograft rejection and cardiac dysfunction , respectively. (6, 7 ) Heart transplant recipients with a prim ary CMV infection have a 46% incidence of developing myocarditis. (8) Approxim ately 50-65% of patients with active myocarditi s are positive for CMV DNA in heart tissues. (9 ) Importantl y, myocardial damage post-CM V infection may persist in immunocom prom ised patients and lead to dilated cardiom yopathy. (10 ) The strict host specificity of CMV has not allowed the development of a direct animal model for human CMV infection. However, murine cytomegaloviru s (MCMV) infection of mice provides an excellent experim ental model because it closely resembles human CMV in gene sequences, tissue tropism, and pathological sequelae. We have demonstrated myocarditis in various inbred strains of mice following sublethal infection with MCMV. (11, 12) An inflamm atory response is first observed in the heart at days 5-7 post infection (p.i.) and persists until at least day 100 p.i. The disease appears to be biphasic with an acute and chronic stage in susceptible strains of mice. Inflammation varies from focal lymphocytic infiltration to intense, difDepartment of Microbiology, University of Western Australia, Nedlands, Perth, Western Australia.
fuse infiltration with degenerative changes ranging from loss of striations, vacuolation, to myofiber drop out. Host genetic factors affect the severity of MCMV-induced myocarditis, however susceptibility does not correlate with the presence of viral antigens in cardiac muscle. (12) Indeed, viral DNA and viral transcripts for immediate early (ie1) genes, as detected by nested PCR, persists out to day 70 in the hearts of both susceptible and resistant mouse strains (Fairweather, Shellam, and Lawson, unpublished data) .
While the pathogenesis of viral myocarditis in humans is not well understood, experimental infection models have increased our understanding of the pathogenic mechanisms involved in the disease. (2) Our previous research has suggested that MCMV-induced myocarditis is immunopatho logical in nature. MCMV-induced myocarditis is associated with the production of autoantibodies to cardiac muscle and an inflammatory infiltrate. We have shown that T cells play a critical role in MCMVinduced myocarditis because athymic mice, in contrast to T cellcom petent mice, do not develop myocarditis. (13) Both CD4 Our previous research has examined heart-reactive IgG antibodies, which are produced early during MCMV infection, peak at days 10-14 p.i., and persist into the late phase of myocarditis (days 28-100 p.i.). (14) The early hum oral immune response is directed against a number of heart proteins, including the contractile proteins troponin, tropomyosin, and myosin, whereas the late immune response is predom inantly directed against the heavy chain of cardiac myosin. (14) We have also found anti-myosin antibodies associated with myocarditis in wild mice that have been naturally infected with MCMV. (15) In addition, MCMV-neutralizing monoclonal antibodies cross-react with cardiac myosin.
(1 6) Therefore, autoimmunity to myosin is a prominent feature of the immune response to MCMV infection.
Absorption experim ents using myosin isoforms revealed that there were differences, both in titer and isoform specificity of anti-myosin antibodies, between mouse strains that are susceptible or resistant to disease. Only mice susceptible to MCMVinduced myocarditis (BALB/c) have a population of antibodies specific for the cardiac isoform of myosin. Although controversy exists as to the direct pathogenic role of antibodies reacting with internal antigens such as myosin, (17,1 8) such autoantibodies appear to play an immunopathog enic role in MCMV-induced myocarditis. (19) We have found that passive transfer of affinity-isolated anti-cardiac myosin antibodies, obtained from late immune sera of MCMV-infected BALB/c mice, induced cellular inflammation and myocardial necrosis in uninfected BALB/c mice. Our model suggests that some anti-CMV antibodies, while highly protective against CMV infection, may also be capable of inducing autoim mune disease.
These cardiac myosin-reactive antibodies (predominantly IgG 2a ) cross-react with MCMV polypeptides (50, 100, 200 KDa) and the S2 region of myosin, suggesting that molecular mimicry between MCMV and cardiac myosin could contribute to the development of MCMV-induced myocarditis. (19) These findings taken together highlight the immunological nature of this disease and provide a basis for the development of immunomodulatory therapies. Our present study uses the well-established mouse model for CMV myocarditis to examine the antiviral and immunomodu latory roles of the type I IFNs (IFN-a /b ) in myocarditis. Our previous studies dem onstrated the efficacy of low-dose orally adm inistered IFN (LDOA IFN) treatment for reduction of early virus replication in the spleen and liver of MCMV-infected mice. (20, 21 ) The oral-mucosal route provides an alternate delivery system to the current modes (system ic delivery) of IFN administration which are limited, due to the production of neutralizing antibodies and may be associated with severe side effects. Treatment with type I IFNs may result in both antiviral and immunomodu latory effects that are less favourable for the developm ent of myocarditis. In particular, we have studied the effects of LDOA IFN treatment of MCMV-infected mice for changes in both the severity and duration of heart disease.
The therapeutic efficacy of LDOA IFN in the development of myocarditis was examined in fem ale adult BALB/c mice (6 weeks old) obtained from Animal Resources Centre (Murdoch, Western Australia). Mice (5/group) were treated with either saline (10 m l/mouse) or type I IFN-a /b (Lee Biomolecular Inc., CA; 10 IU/mouse per day in 10 m l of saline) orally for 7 days prior to intraperitoneal (i.p.) injection with MCMV (a sublethal dose of 10 3 pfu/mouse diluted in 100 m l of pyrogen-free phosphate-buffered saline). A separate group of mice were injected i.p. with 20,000 IU IFN-a /b 6 h prior to MCMV infection. The MCMV stock (K181 strain) was prepared as a 20% salivary gland hom ogenate from virus-infected weanling female BALB/c mice and was titrated in mouse embryo fibroblasts by plaque assay and expressed as pfu/ml as described previously. (22) Hearts from experimental mice were taken at day 6 and day 40 p.i., timepoints representing the acute and chronic stage of myocarditis, transected along the midline, and processed as paraffin embedded blocks. In previous experiments, the average number of foci from serial sections was consistent with the myocarditis score from a single level taken from the interior myocardium (data not shown). Heart sections (two sections cut per mouse with 5 mice/time point) were stained with hematoxylin and eosin (H&E) and were examined histologically for evidence of pathology ( Table 1) . Levels of significance were determined by the unpaired t-test assum ing unequal variance between the means. Mice treated with LDOA IFN had reduced inflammation in the hearts taken at both timepoints (1.8-fold reduction, p # 0.03), indicating that LDOA IFN suppressed the development of myocarditis. The high dose of IFN, injected by the i.p. route, also reduced the severity of both acute (1.6-fold reduction, p # 0.06) and chronic (3.6-fold reduction, p # 0.00001) myocarditis.
To study the effect of LDOA IFN on myocarditis induced by a 10-fold higher dose of virus, BALB/c mice were again treated with either saline or IFN (LDOA and injected high dose) similar to the above experiment but were infected with 10 4 pfu MCMV by the i.p. route. Hearts were exam ined for myocarditis on days 7 and 35 p.i. Again, mice treated with IFN exhibited less severe myocarditis than untreated mice ( Table 2 ). The inflammatory infiltrate of LDOA IFN-treated mice was often more perivascular. Mice receiving LDOA IFN treatment or 20,000 IU IFN (i.p.) showed 1.5-fold reductions (p # 0.04) in the number of inflammatory foci infiltrating the hearts at day 7 p.i. (Table 2 ). At day 35 p.i., mice treated with LDOA IFN displayed a two-fold reduction (p # 0.0007) and mice injected with 20,000 IU IFN showed a three-fold reduction (p # 0.00003) in myocarditis.
LDOA IFN treatm ent reduces MCMV titers in the spleen and liver early in infection. ( 2 0,2 1) To assess further the effect of IFN treatment on virus replication in the infected mice, virus titers in the salivary gland, a site of persistence for MCMV, was quantitated at day 7 p.i. for mice receiving 10 4 pfu MCMV and treated with or without IFN. This time point was chosen because virus does not reach the salivary gland until days 5-7 p.i., unlike virus replication of the spleen and liver, which is first observed at days 2-3 p.i. Individual salivary glands were prepared and titrated in the plaque assay as described previously . (22 ) Virus titers are expressed as mean pfu/g tissue 6 standard error from 5 mice/group (Fig. 1) . The limit of detection of virus was 50 pfu/g tissue. No marked reduction in salivary gland virus titer was observed for mice treated with LDOA IFN. However, mice injected with a high dose of IFN on the day of virus infection show ed significant (p # 0.002) reduction in virus replication in the salivary gland at day 7 p.i. These findings suggest that LDOA IFN treatment does not inhibit either the disseminat ion of virus to the salivary glands or its replication at this distal site, 7 days following i.p. challenge with virus. Interesting ly, this result contrasts the suppression of early replication of disseminat ed MCMV in the liver and spleen observed in LDOA IFN-treated mice at days 2-3 p.i. Therefore, adm inistration of IFN by the oral route appears to have different effects on virus replication depending on the tissue site and/or the kinetics of virus replication in organs. In contrast to the CD8 1 T cell-media ted control of MCMV replication in the spleen and liver, (23 ) control of virus replication in the salivary glands is mediated by CD4 1 T cells. (24) Thus, it is possible that LDOA IFN treatment may have different effects on the stimulatio n of the CD8 1 and CD4 1 T cell-m ediated antiviral immune responses. a Myocarditis was evaluated histologically as the average num ber of inflam matory foci per heart section 6 standard error (two sections were examined from hearts transected through the midline for individual mice from groups of 5 animals).
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b Mice were infected with 1 3 10 3 pfu MCMV by the i.p. route and hearts examined histologically at the specified time points.
c Mice were treated orally with 10 m l of saline/ mouse per day for 1 week prior to virus infection. a Myocarditis was evaluated histologically as the average num ber of inflam matory foci per heart section 6 standard error (two sections were examined from hearts transected through the midline for individual mice from groups of 5 animals).
b Mice were infected with 1 3 10 4 pfu MCMV by the i.p. route, and hearts were examined histologically at the specified time points. It is unlikely that LDOA IFN treatment will prevent the establishmen t of persistence of MCMV in the host, especially the salivary gland, in which there is no evidence of reduction of infectious virus replication. However, our previous studies have shown that MCMV persistence in the salivary gland and low-level transcriptio n of MCMV in the heart does not correlate with susceptibili ty to myocarditis (Fairweather, Shellam, and Lawson, unpublished data). Thus the antiviral effects of the type I IFNs are not entirely responsible for inhibition of the induction of myocarditis.
LDOA type I IFN (10 IU/day for 7 days prior to virus infection) did not completely abrogate myocarditis but suppressed the inflammatory response in both the acute and chronic phases. Furtherm ore, LDOA IFN was as effective at suppressing myocarditis as a single injection of a high dose of IFN (20,000 IU). We propose that predominant immunomodulatory effects of LDOA IFN treatment influence the development of myocarditis following MCMV infection. LDOA IFN therapy may provide a safe alternative in the development of improved clinical treatments of cardiovascular disease. This study provides support for further investigations into the efficacy of LDOA IFN as therapy for cardiovascular disease. The timing and dosage of IFN and the effects of IFN treatment on virus persistence in the heart warrant examination. Furthermore, we have recently shown that there are differential antiviral activities of individual IFN-a subtypes in vivo. (25, 26) It may be necessary to treat myocarditis patients with a particular subtype of IFN-a to achieve optimal protection from disease. These investigations will provide important information on prophylactic therapy for the benefit of people at risk of developing cardiovascular disease.
